



References

1. Cystic Fibrosis Foundation, Patient Registry 2006 Annual Report, Bethesda, Maryland.
2. Li Z, Kosorok M, Farrell P, et al. Longitudinal development of mucoid *Pseudomonas aeruginosa* infection and lung disease progression in children with cystic fibrosis. *JAMA*. 2005;293(5):581-588.
3. Burns J, Saiman L, Whittier S, et al. Comparison of agar diffusion methodologies for antimicrobial testing of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *J Clin Microbiol*. 2000;38(5):1818-1822.
4. Burns J, Saiman L, Whittier S, et al. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Diagn Microbiol Infect Dis*. 2001;39(4):257-260.
5. Saiman L, Burns J, Whittier S, Krzewinski J, Marshall S, Jones R. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of *Pseudomonas aeruginosa* strains isolated from patients with cystic fibrosis. *J Clin Microbiol*. 1999;37(9):2987-2991.
6. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of *Pseudomonas aeruginosa* from patients with cystic fibrosis. *J Clin Microbiol*. 2004;42(5):1915-1922.
7. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. *Am J Respir Crit Care Med*. 2003;167(6):841-849.
8. Comparison of two treatment regimens to reduce PA infection in children with cystic fibrosis (EPIC). Available at: <http://www.ClinicalTrials.gov/ct2/show/NCT00097773>. Accessed December 2008.
9. Ratjen F, Munck A, Kho P. Short and long-term efficacy of inhaled tobramycin in early *P. aeruginosa* infection: the Elite study. *Pediatr Pulmonol*. 2008;43(S31): Abstract 334.
10. Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Döring G. Diagnostic value of serum antibodies in early *Pseudomonas aeruginosa* infection in cystic fibrosis patients. *Pediatr Pulmonol*. 2007;42(3):249-255.

11. West S, Zeng L, Kosorok M, et al. Respiratory infections with *Pseudomonas aeruginosa* in children with cystic fibrosis. Early detection by serology and assessment of risk factors. *JAMA*. 2002;287:2958-2967.
12. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. *Am J Respir Crit Care Med*. 2003;168(8):918-951.
13. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of *Pseudomonas aeruginosa* isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. *Chest*. 2003;123(5):1495-1502
14. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. *Chest*. 2005;128(4):2347-2354.
15. Gee L, Abbott J, Conway SP, Etherington C, Webb AK. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. *Thorax*. 2000;55:946-954.
16. Goldbeck L, Schmitz T, Henrich G, Herschbach P. Questions on life satisfaction for adolescents and adults with cystic fibrosis: development of a disease-specific questionnaire. *Chest*. 2003;123:42-48.
17. Guidance for Industry. Patient-Reported outcome measures: use in medical product development to support labeling claims. Available at: <http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0044-gdl0001.pdf>. Accessed December 2008.
18. Saiman L, Marshall B, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with *Pseudomonas aeruginosa*. A randomized trial. *JAMA*. 2003;290:1749-1756.
19. Donaldson S, Bennett W, Zeman K, Knowles M, Tarran R, Boucher R. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. *New Engl J Med*. 2006;354:241-250.
20. Elkins M, Robinson M, Rose B, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. *New Engl J Med*. 2006;354:229-240.
21. Dupont L, Minic P, Fustic S, et al. A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace™) in the treatment of cystic fibrosis patients with chronic *Pseudomonas aeruginosa* lung infection. *J Cyst Fibrosis*. 2008;7(S2):S26.
22. Charlton B, Lassig A. Inhaled dry powder mannitol (Bronchitol) improves FEV₁ in cystic fibrosis. *J Cyst Fibrosis*. 2006;5(S1):S11.

23. Jaques A, Daviskas E, Turton J, et al. Inhaled mannitol improves lung function in cystic fibrosis. *Chest*. 2008;133:1388-1396.
24. Klijn P, Oudshoorn A, van der Ent C, van der Net J, Kimpen J, Helders P. Effects of anaerobic training in children with cystic fibrosis: a randomized controlled study. *Chest*. 2004;125:1299-1305.
25. Quittner A, Higuchi K, Lewis S, Montgomery AB, Oermann CM. Evaluation of the cystic fibrosis questionnaire-revised (CFQ-R) respiratory scale as a predictor of respiratory hospitalizations in cystic fibrosis patients with *Pseudomonas aeruginosa*. *Pediatr Pulmonol*. 2008;43(S31):307-308. Abstract 301.
26. Moss R. Administration of aerosolized antibiotics in cystic fibrosis patients. *Chest*. 2001;120:107S-113S.
27. Coates A, Leung K, Green M, et al. Lung delivery of a new tobramycin nebulizer solution (150 mg/1.5 mL) by a customized eflow nebulizer is the equivalent of tobi but in a fraction of the time. *Pediatr Pulmonol*. 2008;43(S31): Abstract 462.
28. Retsch-Bogart G, Burns J, Otto K, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and *Pseudomonas aeruginosa* infection. *Pediatr Pulmonol*. 2008;43:47-58.
29. Retsch-Bogart G, McCoy K, Gibson R, Oermann C, Montgomery AB. Source of improvements in lung function in patients with cystic fibrosis (cf) following treatment with aztreonam lysine for inhalation (AZLI). *Pediatr Pulmonol*. 2008;43(S31): Abstract 336.
30. McCoy K, Quittner A, Oermann C, Gibson R, Retsch-Bogart G, Montgomery AB. Inhaled aztreonam lysine for chronic airway *Pseudomonas aeruginosa* in cystic fibrosis. *Am J Resp Crit Care Med*. 2008;178(9):921-928.
31. Moskowitz S, Sliva S, Mayer-Hamblett N, et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. *Pediatr Pulmonol*. 2008;43:874-881.